



IFW


FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

GSHISHIMA@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3081

TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

July 13, 2004

CERTIFICATE OF MAILING 37 C.F.R 1.8	
I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
July 13, 2004	
Date	Gina N. Shishima

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/784,538 entitled "METHODS AND COMPOSITIONS COMPRISING DNA DAMAGING AGENTS AND p53" – Jack Roth et al.*
Our reference: INRP:050USC1
Client reference: MDA90-002CON7


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references A16-A18, B27-B30, and C267-C274.


No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INRP:050USC1.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Gina N. Shishima
Reg. No. 45,104

GNS/kmv
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Application of:
Jack Roth *et al.*

Serial No.: 10/784,538

Filed: February 23, 2004

For: METHODS AND COMPOSITIONS
COMPRISING DNA DAMAGING
AGENTS AND p53

Group Art Unit: 1632

Examiner: Unknown

Atty. Dkt. No.: INRP:050USC1

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

July 13, 2004

Date

Gina N. Shishima

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be


construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/INRP:050USC1.

This application is a continuation application of Serial No. 08/233,002, filed April 25, 1994, now issued as Patent No. 5,747,496 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) only copies of those documents not previously cited and submitted to the Patent and Trademark Office in prior application Serial No. 08/233,002 are enclosed for the convenience of the Examiner.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Gina N. Shishima
Reg. No. 45,104
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: July 13, 2004

Form PTO-1449 (modified)

Atty. Docket No.

INRP:050USC1

Serial No.

10/784,538

List of Patents and Publications for Applicant's

Applicant

Jack Roth *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

February 23, 2004

Group:

1632

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A16	5,366,737	11/22/94	Eppstein <i>et al.</i>	424	450	2/10/93
	A17	5,399,346	3/21/95	Anderson <i>et al.</i>	424	93.21	3/30/94
	A18	6,410,010	6/25/02	Zhang and Roth	424	93.2	10/29/93

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B27	0510691	10/28/92	Europe			English
	B28	2688514	9/17/93	France			Abstract
	B29	WO 93/10814	6/10/93	PCT			English
	B30	WO 93/22443	11/11/93	PCT			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C267	Baker <i>et al.</i> , "Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carinomas," <i>Science</i> , 244:217-221, 1989.
	C268	Culver, <i>et al.</i> , "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors," <i>Science</i> , 256:1550-1552, 1992.
	C269	Nguyen <i>et al.</i> , "Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer," <i>J. Thoracic and Cardiovascular Surgery</i> , 112(5):1372-1377, 1996.
	C270	Parsons <i>et al.</i> , <i>J. Heterocyclic Chem.</i> , 25:911-914, 1988.
	C271	Rubin, <i>Cancer: Principles and Practice of Oncology</i> , 4 th ED. Chapter 16, 276-286, Lippincott-Raven, NY, 1993.
	C272	Shimizu <i>et al.</i> , "Structure of the Ki-ras Gene of the Human Lung Carcinoma Cell Line Calu-1," <i>Nature</i> , 304:497-500, 1983.

25424556.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. INRP:050USC1	Serial No. 10/784,538
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Jack Roth <i>et al.</i>	
		Filing Date: February 23, 2004	Group: 1632
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C273	Smith <i>et al.</i> , "Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice," <i>Nature Genetics</i> , 5:397-402, 1993.
	C274	Stone <i>et al.</i> , "Reversible, p16-mediated cell cycle arrest as protection from chemotherapy," <i>Cancer Res.</i> , 56(14):3199-3202, 1996.

25424556.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.